Health Canada approves new drug to treat patients with Amyotrophic Lateral Sclerosis (ALS)
ALS (also known as Lou Gehrig’s disease) is a disease that gradually causes muscle weakness and disability because the brain progressively loses its capacity to communicate with the muscles of the body. Over time, patients living with ALS will typically experience a progressive loss of their ability to walk, talk, eat, swallow, and eventually breathe.
An estimated 3,000 Canadians are currently living with ALS. Most people with ALS will die within a few years of the diagnosis.
To further reduce any potential delays in accessing edaravone, the Canadian Agency for Drugs and Technologies in Health (CADTH) and l’Institut national d’excellence en santé et en services sociaux (INESSS) started reviewing the drug for possible reimbursement through publicly funded drug plans while Health Canada’s review was still underway.
As it does with all drugs authorized for sale in Canada, Health Canada will continue to monitor edaravone for any safety concerns and will take appropriate action if required.
Public Health Agency of Canada
Report a problem or mistake on this page
- Date modified: